NCT03655210View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

272

Participants

Timeline

Start Date

February 7, 2017

Primary Completion Date

February 20, 2017

Study Completion Date

October 16, 2017

Conditions
Perennial Allergic Rhinitis
Interventions
DRUG

HL151

HL151(1Tab) once a day for 4 weeks of treatments

DRUG

placebo

HL151 placebo(1Tab, Placebo of Bepostatine salicylate) once a day for 4 weeks of treatments

Trial Locations (1)

13620

Seoul National University Hospital, Gyeonggi-do

All Listed Sponsors
lead

Hanlim Pharm. Co., Ltd.

INDUSTRY

NCT03655210 - To Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients | Biotech Hunter | Biotech Hunter